- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT00005242
Childhood Passive Smoking: Cohort Study of Cardiac Risk
Studie Overzicht
Toestand
Gedetailleerde beschrijving
BACKGROUND:
The adverse health effects of actively inhaled cigarette smoke include impaired pulmonary function, increased coronary and cerebrovascular disease, chronic pulmonary disease, and cancer. Infants and young children of smoking parents are at increased risk for lower respiratory tract infections and small airways disease than are children of non-smoking parents. What is less clear is how the oxygen transport system of the growing child is affected by the long-term exposure to and passive inhalation of cigarette smoke and if this exposure represents a risk for the subsequent development of atherosclerotic heart disease.
DESIGN NARRATIVE:
A sample of 300 pre-adolescent twin pairs was recruited from an established population-based twin study. The three cohorts of twins and their parents were initially evaluated in a cross-sectional study and then followed longitudinally for up to three years. In the initial testing cycle the following data were collected: genotype; general health; anthropometric measures; resting and exercise noninvasive evaluation of hemodynamic parameters including blood pressure, heart rate, cardiac output, left ventricular mass, and oxygen consumption; hematocrit and blood levels of 2,3-DPG, cotinine, thiocyanate, and erythropoietin; spirometric and pulmonary flow data; lipid levels. There were three follow-up exams. The availability of repeated measures of oxygen delivery and its determinants in twins and their parents permitted both a unique analysis of genetic and environmental factors during the process of developmental change and measurements of the risks of accelerated atherosclerotic/ischemic heart disease and of the development of reactive airway disease.
The following hypotheses were tested: genetic factors accounted for a significant proportion of the variation in the hematologic and cardiovascular determinants of systemic oxygen delivery; adaptive responses of the oxygen delivery system differed in the same individual before and after puberty; passive smoking in children was an incremental risk factor for the development of accelerated atherosclerotic/ischemic cardiovascular disease; passive smoking in children was a contributing factor in the development of reactive airway disease.
Studietype
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Studie plan
Hoe is de studie opgezet?
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Algemene publicaties
- Moskowitz WB, Mosteller M, Schieken RM, Bossano R, Hewitt JK, Bodurtha JN, Segrest JP. Lipoprotein and oxygen transport alterations in passive smoking preadolescent children. The MCV Twin Study. Circulation. 1990 Feb;81(2):586-92. doi: 10.1161/01.cir.81.2.586.
- Schieken RM, Mosteller M, Goble MM, Moskowitz WB, Hewitt JK, Eaves LJ, Nance WE. Multivariate genetic analysis of blood pressure and body size. The Medical College of Virginia Twin Study. Circulation. 1992 Dec;86(6):1780-8. doi: 10.1161/01.cir.86.6.1780.
- Goble MM, Mosteller M, Moskowitz WB, Schieken RM. Sex differences in the determinants of left ventricular mass in childhood. The Medical College of Virginia Twin Study. Circulation. 1992 May;85(5):1661-5. doi: 10.1161/01.cir.85.5.1661.
- Newkumet KM, Goble MM, Young RB, Kaplowitz PB, Schieken RM. Altered blood pressure reactivity in adolescent diabetics. Pediatrics. 1994 Apr;93(4):616-21.
- Moskowitz WB, Mosteller M, Hewitt JK, Eaves LJ, Nance WE, Schieken RM. Univariate genetic analysis of oxygen transport regulation in children: the Medical College of Virginia Twin Study. Pediatr Res. 1993 Jun;33(6):645-8. doi: 10.1203/00006450-199306000-00022.
Studie record data
Bestudeer belangrijke data
Studie start
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 1123 (WRAIR)
- R29HL038878 (Subsidie/contract van de Amerikaanse NIH)
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Hartziekten
-
University Hospital TuebingenVoltooidHeart Assist-apparaatDuitsland
-
University of ChicagoVoltooidHartfalen | Heart Assist-apparaat | HyponatremischVerenigde Staten
-
Carmel Medical CenterOnbekendPneumoperitoneum | Heart Output StoornisIsraël
-
Region SkaneAanmelden op uitnodigingHartfalen New York Heart Association (NYHA) Klasse II | Hartfalen New York Heart Association (NYHA) Klasse IIIZweden
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University... en andere medewerkersNog niet aan het wervenHartfalen, systolisch | Hartfalen met verminderde ejectiefractie | Hartfalen New York Heart Association Klasse IV | Hartfalen New York Heart Association Klasse IIIPolen
-
Triple-Gene, LLCIntrexon Corporation; Precigen, IncVoltooidHart-en vaatziekten | Hartfalen | Heart-Assist-apparaatVerenigde Staten
-
University of WashingtonAmerican Heart AssociationVoltooidHartfalen, congestief | Mitochondriale verandering | Hartfalen New York Heart Association Klasse IVVerenigde Staten
-
Novartis PharmaceuticalsVoltooidPatiënten die de behandelingsperiode van 12 maanden van de kernstudie met succes hebben afgerond (de Novo Heart-ontvangers) die geïnteresseerd waren om behandeld te worden met EC-MPS
-
University of PennsylvaniaVoltooidPatiënten met primaire of secundaire diagnose Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Behalve wanneer het 5e cijfer 2 was)Verenigde Staten
-
SpringWorks Therapeutics, Inc.VerkrijgbaarNeurofibromatose Type 1-geassocieerde plexiforme neurofibromen | Histiocytisch neoplasma | Andere MAP-K Pathway Driven Diseases